These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15137932)

  • 21. Antipsychotic polypharmacy: do benefits justify the risks?
    Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
    Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
    [No Abstract]   [Full Text] [Related]  

  • 22. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study.
    Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
    Katona L; Czobor P; Bitter I
    Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of clozapine on polypharmacy.
    Chong SA; Remington GJ; Bezchlibnyk-Butler KZ
    Psychiatr Serv; 2000 Feb; 51(2):250-2. PubMed ID: 10655014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    Kessler RM
    Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
    [No Abstract]   [Full Text] [Related]  

  • 26. Antipsychotic polypharmacy is not associated with reduced dose of individual antipsychotics in schizophrenia.
    John AP; Dragovic M
    J Clin Psychopharmacol; 2015 Apr; 35(2):193-5. PubMed ID: 25679123
    [No Abstract]   [Full Text] [Related]  

  • 27. Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?
    Meltzer HY
    Biol Psychiatry; 1999 Jul; 46(1):144-9. PubMed ID: 10394487
    [No Abstract]   [Full Text] [Related]  

  • 28. Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit.
    Lerma-Carrillo I; de Pablo Brühlmann S; del Pozo ML; Pascual-Pinazo F; Molina JD; Baca-García E
    Clin Neuropharmacol; 2008; 31(6):319-32. PubMed ID: 19050409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polypharmacy in schizophrenia.
    Zink M; Englisch S; Meyer-Lindenberg A
    Curr Opin Psychiatry; 2010 Mar; 23(2):103-11. PubMed ID: 20051861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
    Wu YH; Lai CY; Chang YS
    Psychogeriatrics; 2015 Mar; 15(1):7-13. PubMed ID: 25515355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: an analysis of the CATIE data.
    Takeuchi H; Suzuki T; Bies RR; Remington G; Mamo DC; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2013 Nov; 150(2-3):373-9. PubMed ID: 24028745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison.
    Roh D; Chang JG; Kim CH; Cho HS; An SK; Jung YC
    Aust N Z J Psychiatry; 2014 Jan; 48(1):52-60. PubMed ID: 23671214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D2 receptors as treatment targets in schizophrenia.
    Seeman P
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009).
    Xiang YT; Wang CY; Si TM; Lee EH; He YL; Ungvari GS; Chiu HF; Yang SY; Chong MY; Tan CH; Kua EH; Fujii S; Sim K; Yong KH; Trivedi JK; Chung EK; Udomratn P; Chee KY; Sartorius N; Shinfuku N
    Pharmacopsychiatry; 2012 Jan; 45(1):7-12. PubMed ID: 21989602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Proposal for Natural Resilience Theory in Psychopharmacotherapy: To Deter High-dose Antipsychotic Polypharmacy].
    Yagi G; Suzuki T; Uchida H
    Seishin Shinkeigaku Zasshi; 2015; 117(1):10-7. PubMed ID: 26514041
    [No Abstract]   [Full Text] [Related]  

  • 37. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.
    Velligan DI; Carroll C; Lage MJ; Fairman K
    Psychiatr Serv; 2015 Feb; 66(2):127-33. PubMed ID: 25321616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Quetiapine].
    Kusumi I
    Nihon Rinsho; 2013 Apr; 71(4):673-7. PubMed ID: 23678598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.
    Gören JL; Meterko M; Williams S; Young GJ; Baker E; Chou CH; Kilbourne AM; Bauer MS
    Psychiatr Serv; 2013 Jun; 64(6):527-33. PubMed ID: 23450334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.